Floatz logo

Abciximab

Cerebrovascular Accident

University of Zurichmonoclonal_antibodyPhase 3Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

133 Active assets in the Cerebrovascular Accident cohort.

Asset / SponsorPhaseRating
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
Aggrenox
Boehringer Ingelheim
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Tenecteplase
Assistance Publique - Hôpitaux de Paris
Phase 4BBB

View all 50 →

Same molecule, other indications

Abciximab is also rated in:

brain ischemiaDormant
CC
Indicative ·
42 / 100
View asset →
acute diseaseDormant
CC
Indicative ·
42 / 100
View asset →
sickle cell diseaseDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →